The New England journal of medicine
-
Comment Letter
Tirzepatide Once Weekly for the Treatment of Obesity. Reply.
-
Randomized Controlled Trial Multicenter Study Comparative Study
Trial of Endovascular Treatment of Acute Basilar-Artery Occlusion.
Data from trials investigating the effects and risks of endovascular thrombectomy for the treatment of stroke due to basilar-artery occlusion are limited. ⋯ In a trial involving Chinese patients with basilar-artery occlusion, approximately one third of whom received intravenous thrombolysis, endovascular thrombectomy within 12 hours after stroke onset led to better functional outcomes at 90 days than best medical care but was associated with procedural complications and intracerebral hemorrhage. (Funded by the Program for Innovative Research Team of the First Affiliated Hospital of USTC and others; ATTENTION ClinicalTrials.gov number, NCT04751708.).
-
Randomized Controlled Trial Multicenter Study
Five-Year Outcomes of the Danish Cardiovascular Screening (DANCAVAS) Trial.
Limited data suggest a benefit of population-based screening for cardiovascular disease with respect to the risk of death. ⋯ After more than 5 years, the invitation to undergo comprehensive cardiovascular screening did not significantly reduce the incidence of death from any cause among men 65 to 74 years of age. (Funded by the Southern Region of Denmark and others; DANCAVAS ISRCTN Registry number, ISRCTN12157806.).
-
Randomized Controlled Trial Comparative Study
Trial of Thrombectomy 6 to 24 Hours after Stroke Due to Basilar-Artery Occlusion.
The effects and risks of endovascular thrombectomy 6 to 24 hours after stroke onset due to basilar-artery occlusion have not been extensively studied. ⋯ Among patients with stroke due to basilar-artery occlusion who presented 6 to 24 hours after symptom onset, thrombectomy led to a higher percentage with good functional status at 90 days than medical therapy but was associated with procedural complications and more cerebral hemorrhages. (Funded by the Chinese National Ministry of Science and Technology; BAOCHE ClinicalTrials.gov number, NCT02737189.).